Carlo Brugnara

Laboratory Medicine, Children's Hospital Boston, United States of America

Carlo Brugnara, MD

Academic positions:
- Professor of Pathology, Harvard Medical School
- Director, Hematology Laboratory, Children's Hospital, Boston

All industry positions (in last five years):
None declared

Research interests:
Dr Brugnara's research is focused on regulation of cell volume and transport of ions across the cell membrane. His studies have described the role of specific transport proteins in inducing erythrocyte dehydration in sickle cell disease. His work has suggested several new potential therapeutic approaches for sickle cell disease, including an ion channel blocker (ICA-17043), oral Mg supplements (Mg-pidolate), inhaled nitric oxide (NO).

Dr. Brugnara's clinical laboratory-based research has been focused on the use of hematological parameters to assess the balance between iron availability and erythropoiesis. He has described the appearance of functional iron deficiency in normal subjects treated with recombinant human erythropoietin (r-HuEPO) based on the particular flow cytometric characteristics of erythrocytes and reticulocytes. He has shown the clinical value of reticulocyte parameters in the setting of r-HuEPO use and in the diagnosis of iron deficiency in children.

Any other information:
Dr. Brugnara is a fellow of the American Society of Clinical Investigation, the Association of American Physicians, and the Academy of Clinical Laboratory Physicians and Scientists. He is on the editorial board of Blood, Clinical Chemistry, BloodLine, and Haematologica.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Hematology > Anemias & Hypocellular Marrow Disorders (since 30 May 2006)

Links

http://www.childrenshospital.org/cfapps/research/data_admin/Site184/mainpageS184P0.html

All recent recommendations

• 6.0
  Blood doping in athletes-Detection of allogeneic blood transfusions by flow cytofluorometry.
  Recommended by Carlo Brugnara
  
• 8.0
  Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).
  Recommended by Carlo Brugnara, Philipp M Lepper
  
• 3.0
  K-CL co-transport plays an important role in normal and beta thalassemic erythropoiesis.
  Recommended by Carlo Brugnara
  
• 3.0
  Sickle cell vasoocclusion and rescue in a microfluidic device.
  Recommended by Carlo Brugnara
  
• 3.0
  Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
  Recommended by Carlo Brugnara
  
• 3.0
  Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy.
  Recommended by Carlo Brugnara
  
• 3.0
  Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease.
  Recommended by Carlo Brugnara